🇺🇸 FDA
Patent

US 6537804

BCR-ABL directed compositions and uses for inhibiting Philadelphia chromesome stimulated cell growth

expired A61KA61K38/00A61P

Quick answer

US patent 6537804 (BCR-ABL directed compositions and uses for inhibiting Philadelphia chromesome stimulated cell growth) held by The Board of Regents of the University of Texas System expires Mon Mar 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Mar 25 2003 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K38/00, A61P, A61P31/12